Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
Fakhouri, Fadi; Fila, Marc; Provôt, François; Delmas, Yahsou; Barbet, Christelle; Châtelet, Valérie; Rafat, Cédric; Cailliez, Mathilde; Hogan, Julien; Servais, Aude; Karras, Alexandre; Makdassi, Raifah; Louillet, Feriell; Coindre, Jean-Philippe; Rondeau, Eric; Loirat, Chantal; Frémeaux-Bacchi, Véronique.
Clin J Am Soc Nephrol
; 12(1): 50-59, 2017 01 06.
Artigo em Inglês | MEDLINE | ID: mdl-27799617
The clinical spectrum of hemolytic uremic syndrome secondary to complement factor H autoantibodies.
Disease Recurrence After Early Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome With Complement C3 I1157T Mutation.
Atypical hemolytic uremic syndrome: from diagnosis to treatment.
Adult Post-Kidney Transplant Familial Atypical Hemolytic Uremic Syndrome Successfully Treated With Eculizumab: A Case Report and Literature Review.
A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.
Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH.
Favorable long-term outcomes of isolated liver transplantation in a child with atypical hemolytic uremic syndrome caused by a novel complement factor H mutationâ©.
Genetic predisposition to infection in a case of atypical hemolytic uremic syndrome.
Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension.
Neonatal atypical hemolytic uremic syndrome from a factor H mutation treated with eculizumab.